20/20 Biolabs, Inc.
AIDX
Analytical Summary
20/20 Biolabs, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.
3-Year Financial Trajectory
AnnualBullish Indicators
- No bullish signals detected.
Bearish Risks
- Operating Margin (%)Operating Margin (%) is in the bottom quartile
- Profit Margin (%)Profit Margin (%) is in the bottom quartile
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|
| Revenue Growth YoY (%) |
16.7%
Good
Good
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Above avg (+234%)
|
— | — |
| EPS Growth YoY (%) |
34.5%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — |
| Net Income Growth YoY (%) |
32.7%
Excellent
Excellent
Year-over-year change in net income |
— | — |
| FCF Growth YoY (%) |
28.1%
Excellent
Excellent
Year-over-year change in free cash flow |
— | — |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|
| Operating Margin (%) (%) |
-162.9%
Weak
Weak
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-1457%)
|
-324.0%
Weak
Weak
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-2800%)
|
— |
| Profit Margin (%) (%) |
-182.8%
Weak
Weak
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-2385%)
|
-316.8%
Weak
Weak
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Below avg (-4060%)
|
— |
| FCF Margin (%) (%) |
-93.9%
Weak
Weak
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
-148.3%
Weak
Weak
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
— |
| FCF / Net Income (x) |
0.51x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.47x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|
| Return on Invested Capital (%) |
13687.3%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
-297.9%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-80.5%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-158.4%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— |
Secondary lens
Benchmark Lens
Compare AIDX against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare AIDX against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for AIDX
No bullish signals detected
Operating Margin (%) is in the bottom quartile
Profit Margin (%) is in the bottom quartile
Percentile Rankings
How AIDX compares to all companies
Peer Comparison
AIDX vs similar peers
Compare AIDX with peers
Stack AIDX against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 5 days ago 3 years · 7 quarters